Heraeus expands and diversifies its medical technology portfolio

Heraeus acquires Mo-Sci Corporation, a world leader in medical and specialty glass technologies, and ETS Technology Holdings

Heraeus Group, a leading international family-owned portfolio company, has announced its acquisition of Mo-Sci Corporation (“Mo-Sci”) a world leader in the supply of medical and specialty glass and ETS Technology Holdings, LLC (“ETS”), a provider of innovative wound care technologies. Both companies are located in Rolla, Missouri, USA.

Custom glass solution for unique applications

Mo-Sci was founded by Dr. Delbert Day in 1985 to develop and supply specialty glass and ceramic products for specific market applications. Today, Mo-Sci is a leading supplier to the medical device industry with glass microspheres, fibers, and powders. It also provides sealing glass and test services for the aerospace, automotive, and electronics industries. The company was led by Ted Day, Delbert’s son, up until his passing in September 2020.

Advanced wound healing through synthetic, absorbable, bioactive glass fibre technology

ETS was founded in 2012 to develop and commercialize a novel borate-based bioactive glass technology platform for wound care and hemostasis. ETS received FDA clearance for its first product, Mirragen, a resorb-able synthetic skin substitute, and continues to expand the technology to new applications.

Nicolas Guggenheim, Head of Business Area Medical Technologies, said, “Across every treatment area, medical technology is changing rapidly. The acquisition of Mo-Sci and ETS gives us new capabilities to help our customers deliver innovative technologies and breakthrough treatments that will improve outcomes and patient care.”

Kimberly Day, the owner of Mo-Sci and ETS, said. “Mo-Sci and Heraeus have been in contact for many years and prior to his passing, Ted identified Heraeus as a preferred partner to take Mo-Sci and ETS to the next stage of development. I am glad to carry this vision through to completion.” Heraeus plans to keep the existing Mo-Sci team and facilities in Rolla.

The acquisition is expected to close by the end of 2021, pending legal clearance and satisfaction of customary closing conditions.